CACNA2D2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL116362	0.45	11/20
SCHEMBL619154	0.41	7/20
SCHEMBL620978	0.40	7/20
SCHEMBL621013	0.40	7/20
SCHEMBL621555	0.39	6/20
SCHEMBL617973	0.38	6/20
SCHEMBL1810921	0.51	5/20
SCHEMBL620400	0.44	5/20
SCHEMBL620595	0.44	5/20
SCHEMBL619405	0.43	5/20
SCHEMBL618375	0.37	5/20
SCHEMBL2034740	0.46	4/20
SCHEMBL1148581	0.40	4/20
SCHEMBL618949	0.37	4/20
SCHEMBL621148	0.35	4/20
SCHEMBL941502	0.50	3/20
SCHEMBL2273040	0.50	3/20
Hydroxyamine (SCHEMBL2034741)	0.47	3/20
SCHEMBL2074365	0.46	3/20
SCHEMBL163226	0.45	3/20

Clinical trials — most relevant to CACNA2D2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Role of Intralipid in Management of Organophosphorus Poisoning	PHASE2/PHASE3	WITHDRAWN
4-Aminopyridine in Episodic Ataxia Type 2	PHASE2	WITHDRAWN
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients	PHASE2	WITHDRAWN
Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI	PHASE2	COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients	PHASE2	WITHDRAWN
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome	PHASE1/PHASE2	NOT_YET_RECRUITING
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development	nan	RECRUITING
Calciotropic Effects After HCG Stimulation Test	nan	COMPLETED
MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants	nan	RECRUITING
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13)	nan	NOT_YET_RECRUITING
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Urine Concentration of S100B in Extremely Premature Infants	nan	COMPLETED
Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy	nan	COMPLETED
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease	nan	UNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Human Epilepsy Genetics--Neuronal Migration Disorders Study	nan	RECRUITING
DNA Analysis From Isolated Cardiomyocytes in the Molecular Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia	nan	COMPLETED
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life	nan	COMPLETED
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors	nan	UNKNOWN
Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias	nan	RECRUITING
FAPI PET/CT Imaging in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) (FAPI-ARVC))	nan	RECRUITING
Medtronic Genetic Arrhythmia Markers for Early Detection (GAME Study)	nan	COMPLETED
United States Hypophosphatasia Molecular Research Center	nan	COMPLETED
Assessing Bone Calcium Content in Children With Kidney Disease Treated With Two Different Medicines	nan	UNKNOWN
LAMA2-related Muscular Dystrophy Brain Study	nan	WITHDRAWN
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)	nan	COMPLETED
Artificial Intelligence for the Prioritization of Genetic Background in Brugada Syndrome	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CACNA2D2 binder may also engage these)

Protein	Name	Similarity
Q8CFG6	—	1.000	Q8CFG6 →
Q6PHS9	—	1.000	Q6PHS9 →
O08532	—	0.987	O08532 →
P13806	—	0.986	P13806 →
P54290	—	0.984	P54290 →
CACNA2D1	Voltage-dependent calcium channel subunit alpha-2/delta-1	0.981	landscape →
Q5U4X8	—	0.958	Q5U4X8 →
Q6GQK9	—	0.953	Q6GQK9 →
Q6ZQ11	—	0.953	Q6ZQ11 →
Q86X52	—	0.953	Q86X52 →
Q98864	—	0.951	Q98864 →
Q9EQW8	—	0.951	Q9EQW8 →
Q9EQH7	—	0.951	Q9EQH7 →
Q6IS24	—	0.949	Q6IS24 →
Q9HCM2	—	0.948	Q9HCM2 →
Q80UG2	—	0.948	Q80UG2 →
O75051	—	0.948	O75051 →
Q9H3R1	—	0.948	Q9H3R1 →
Q5R6K5	—	0.947	Q5R6K5 →
O70309	—	0.946	O70309 →
Q9R0E1	—	0.946	Q9R0E1 →
Q7TT15	—	0.946	Q7TT15 →
A5D7I4	—	0.946	A5D7I4 →
Q9H6X2	—	0.946	Q9H6X2 →
Q91YD4	—	0.946	Q91YD4 →
Q9CZ52	—	0.946	Q9CZ52 →
Q3UHN9	—	0.945	Q3UHN9 →
ITGB5	Integrin beta-5	0.945	landscape →
Q8BJQ9	—	0.945	Q8BJQ9 →
P97464	—	0.945	P97464 →